PT  - JOURNAL ARTICLE
AU  - Milaneschi, Yuri
AU  - Arnold, Matthias
AU  - Kastenmüller, Gabi
AU  - Dehkordi, Siamak Mahmoudian
AU  - Krishnan, Ranga R.
AU  - Dunlop, Boadie W.
AU  - Rush, A. John
AU  - Penninx, Brenda W. J. H.
AU  - Kaddurah-Daouk, Rima
AU  - ,
TI  - Genomics-based identification of a potential causal role for acylcarnitine metabolism in depression
AID  - 10.1101/2021.10.18.21265157
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.10.18.21265157
4099  - http://medrxiv.org/content/early/2021/10/19/2021.10.18.21265157.short
4100  - http://medrxiv.org/content/early/2021/10/19/2021.10.18.21265157.full
AB  - Altered metabolism of acylcarnitines – transporting fatty acids to mitochondria – may represent a mechanism linking cellular energy dysfunction to depression. We examined the potential causal role of acylcarnitine metabolism in depression by leveraging genomics and Mendelian randomization. Summary statistics were obtained from large GWAS: the Fenland Study (N= 9,363), and the Psychiatric Genomics Consortium (246,363 depression cases and 344,901 controls). Two-sample Mendelian randomization analyses tested the potential causal link of 15 endogenous acylcarnitines with depression. In univariable analyses, genetically-predicted lower levels of short-chain acylcarnitines C2 (Odds Ratio [OR] 0.97, 95% Confidence Intervals [CIs] 0.95-1.00) and C3 (OR 0.97, 95%CIs 0.96-0.99) and higher levels of medium-chain acylcarnitines C8 (OR 1.04, 95%CIs 1.01-1.06) and C10 (OR 1.04, 95%CIs 1.02-1.06) were associated with increased depression risk. No reverse potential causal role of depression genetic liability on acylcarnitines levels was found. Multivariable analyses showed that the association with depression was driven by the medium-chain acylcarnitines C8 (OR 1.04, 95%CIs 1.02-1.06) and C10 (OR 1.04, 95%CIs 1.02-1.06), suggesting a potential causal role of these acylcarnitines in the risk of depression. Causal estimates for C8 (OR=1.05, 95%CIs=1.02-1.07) and C10 (OR=1.05, 95%CIs=1.02-1.08) were confirmed in follow-up analyses using genetic instruments derived from a GWAS meta-analysis including up to 16,841 samples. Accumulation of medium-chain acylcarnitines is a signature of inborn errors of fatty acid metabolism and age-related metabolic conditions. Our findings point to a link between altered mitochondrial energy production and depression pathogenesis. Acylcarnitine metabolism represents a promising access point for the development of novel therapeutic approaches for depression.Competing Interest StatementBWJHP has received research funding (unrelated to the work reported here) from Jansen Research and Boehringer Ingelheim. A. John Rush has received consulting fees from Compass Inc., Curbstone Consultant LLC, Emmes Corp., Evecxia Therapeutics, Inc., Holmusk, Johnson and Johnson (Janssen), Liva-Nova, Neurocrine Biosciences Inc., Otsuka-US; speaking fees from Liva-Nova, Johnson and Johnson (Janssen); and royalties from Guilford Press and the University of Texas Southwestern Medical Center, Dallas, TX (for the Inventory of Depressive Symptoms and its derivatives). He is also named co-inventor on two patents: U.S. Patent No. 7,795,033: Methods to Predict the Outcome of Treatment with Antidepressant Medication, Inventors: McMahon FJ, Laje G, Manji H, Rush AJ, Paddock S, Wilson AS; and U.S. Patent No. 7,906,283: Methods to Identify Patients at Risk of Developing Adverse Events During Treatment with Antidepressant Medication, Inventors: McMahon FJ, Laje G, Manji H, Rush AJ, Paddock S. M.A. and G.K. are co-inventors (through Duke University/Helmholtz Zentrum Munchen) on patents on applications of metabolomics in diseases of the central nervous system; M.A. and G.K. hold equity in Chymia LLC and IP in PsyProtix and Atai that are exploring the potential for therapeutic applications targeting mitochondrial metabolism in depression. S.M. is an inventor on patents in the Metabolomics field. R.R.K. is CEO of Rush University System for Health, Chairman of National Medical Research Council Ministry of Health Singapore, Chairman of Amyriad, BV Board member Community Health Systems, Advisory board SageRx, Verily Patents on Brain Computer Interface licensed to Psyber and ATAI, an inventor of Metabolomics patents in the CNS field including patents licensed to Chymia LLC and PsyProtix with royalties and ownership. R.K.-D. is funded by National Institute on Aging [U01AG061359, R01AG057452, RF1AG051550, and R01AG046171] and National Institute of Mental Health [R01MH108348]. This funding enabled consortia that she leads including the Mood Disorder Precision Medicine Consortium, the Alzheimer disease Metabolomics Consortium, and the Alzheimer Gut Microbiome Project that contributed to acylcarnitine discoveries. She is an inventor on key patents in the field of Metabolomics and hold equity in Metabolon, a biotech company in North Carolina. In addition, she holds patents licensed to Chymia LLC and PsyProtix with royalties and ownership. The funders listed above had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the paper; and decision to submit the paper for publication. B.W.D has received research support from Acadia, Compass, Aptinyx, NIMH, Sage, Otsuka, and Takeda, and has served as a consultant to Greenwich Biosciences, Myriad Neuroscience, Otsuka, Sage, and Sophren Therapeutics. All the other authors declare no conflict of interest.Funding StatementYM and BWJHP acknowledge the following funding: this project has received funding from the European Union Horizon 2020 research and innovation programme under grant agreement No 8481464 In addition, the work was funded through NIMH grant number R01MH108348 and through a series of grants issued to Dr. Kaddurah-Daouk (PI) through NIA including U01AG061359, RF1AG057452, and RF1AG051550 that supported large number of scientists working on metabolomics and neuropsychiatric disorders and role for acylcarnitines. M.A. and G.K. received funding (through their institutions) from the National Institutes of Health/National Institute on Aging through grants RF1AG058942, RF1AG059093, U01AG061359, U19AG063744, and R01AG069901. The Fenland Study (10.22025/2017.10.101.00001) is funded by the Medical Research Council (MC_UU_12015/1). We further acknowledge support for genomics from the Medical Research Council (MC_PC_13046).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Summary statistics for ACs were retrieved from a GWAS in 9,363 samples from the Fenland study. GWAS summary statistics of genotype-metabolite associations are made available through an interactive web server (https://omicscience.org/apps/crossplatform/). Access to individual-level data can be requested at https://epi-meta.mrc-epid.cam.ac.uk/. GWAS summary statistics for depression were obtained from the Psychiatric Genomics Consortium (PGC) overarching meta-analysis of datasets with depression phenotypes, totaling 246,363 cases and 344,901 controls. The statistics publicly available here https://www.med.unc.edu/pgc/download-results/ are based on a GWAS meta-analysis not including 23andMe data, access to which is restricted by a Data Transfer Agreement. Full summary statistics for the metabolite GWAS meta-analysis by Draisma et al.(3) on 7,478 samples from seven European cohorts are available at https://dataverse.nl/dataset.xhtml?persistentId=doi:10.34894/JFWWS4I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe present study is based on analyses applied to GWAS summary statistics that are available via the respective studies and consortia webportals. https://omicscience.org/apps/crossplatform/ https://www.med.unc.edu/pgc/download-results/ https://dataverse.nl/dataset.xhtml?persistentId=doi:10.34894/JFWWS4